A complete application in a minute
Tailored resume and cover letter, ready to send.
Oslo University Hospital, a leading regional hospital, hosts the Translational Research Unit within the InnovaRTBRAIN network. The PhD positions focus on innovative radiotherapy and CAR-/TCR-based therapies for solid cancers.
You will be embedded in an internationally oriented research environment and trained in open science, ethics, data management, and entrepreneurship. The 5-year Master requirement is aimed at completing a PhD by February 2027, with opportunities to contribute to
Glioblastoma multiforme (GBM) is among the most lethal human cancers. The standard treatment—surgery followed by radiotherapy (RT) and temozolomide (TMZ) provides a median survival of around 14 months and is often accompanied by severe toxicity. Recurrence occurs in 90% of patients within 2 years, while re-irradiation and alternative treatments are constrained by high morbidity.
Novel therapeutic approaches that address the main challenges in GBM treatments are urgently needed and include I) radioresistance, II) infiltration, and III) immunosuppression. The main objective of InnovaRTBRAIN – Innovative Radiation Therapy for Brain Tumors – is to tackle those challenges by means of innovative radiotherapy and employing a holistic approach.
In this context, thanks to a network of 23 partners InnovaRTBRAIN aims to train 14 doctoral researchers to enhance the efficacy of innovative radiotherapy through combination with immunotherapies. Research and transferable training of the doctoral researchers will be performed in a highly interdisciplinary, intersectoral, and international environment. In addition to acquiring skills related to the research project, they will be trained also in open science, communication and dissemination, responsible research and innovation, circular economy, ethics, data management, entrepreneurship, marketing, intellectual property, and gender dimension in research.
Oslo University Hospital (OUH) is a highly specialised hospital in charge of extensive regional and local hospital assignments and the provision of high quality services for the citizens of Oslo. The hospital also has nationwide responsibility for a number of national and multi-regional assignments and has several national centres of competence. OUH carries out advanced patient treatment, research and clinical trial treatments, and give advice and provide education on international levels. The hospital is Scandinavia’s largest and annually performs more than 1.2 million patient treatments.
The Department of Oncology is located at one site, The Norwegian Radiumhospital. The department carries out intensive research on new cancer treatment methods.
The PHD position is available in the Translational Research Unit, at the Section for Cellular Therapy. The section has a clinical unit producing cell therapy products for patient treatment and a Translational Research Unit developing new types of CAR- and TCR-based treatment for solid cancers.
Oslo University Hospital is a workplace with great diversity. We believe this is essential to perform the tasks required. We pursue diversity among our job applicants and encourage everyone to apply regardless of who you are and what background you have.
We are looking for a student with a 5-years degree (Master) in biology, immunology, biotechnology, or related fields.
The candidate must have experience with cellular biology (cell culture, cell transfection, basic molecular biology ((DNA manipulation, cloning), and strong knowledge of immunology (at least theoretical).
The candidate must be ready to perform in vivo experiments including surgery.
Knowledge and practical experience in any of the following techniques will be considered and advantage:
The candidate must not have resided or carried out their main activity (work, studies, etc.) in Norway for more than 12 months in the 3 years immediately before the recruitment date. Compulsory national service, short stays such as holidays, and time spent as part of a procedure for obtaining refugee status under the Geneva Convention are not considered.
The candidate, at the time of recruitment by Oslo University Hospital, Norway, must not be enrolled in a doctoral school or have been awarded a doctoral degree.
All applications will be checked for eligibility (in particular, the adherence to the mobility rule). Incomplete, longer or AI-generated applications will not be selected. Shortlisted candidates will be invited for an interview. Candidates will be notified of the outcome as soon as possible. Start of employment is foreseen March 2027.
Equal opportunities policy without distinction on the grounds of gender, racial or ethnic origin, religion or belief, disability, age or sexual orientation will be applied.
The selection is not limited to EU citizens; therefore, candidates can be of any nationality.